These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27815867)

  • 1. Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Xu S; De Porre P
    Clin Pharmacokinet; 2017 Feb; 56(2):213-214. PubMed ID: 27815867
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Srinivas NR
    Clin Pharmacokinet; 2017 Feb; 56(2):211-212. PubMed ID: 27815866
    [No Abstract]   [Full Text] [Related]  

  • 3. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Jul; 196(1):103. PubMed ID: 27321503
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 7. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
    O'Reilly D
    Clin Genitourin Cancer; 2019 Oct; 17(5):e886-e887. PubMed ID: 31409550
    [No Abstract]   [Full Text] [Related]  

  • 9. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
    Ma H; Zhu G; Wan B; Wu PJ; Wang JY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.
    Agarwal N; Alex AB; Farnham JM; Patel S; Gill D; Buckley TH; Stephenson RA; Cannon-Albright L
    J Urol; 2016 Oct; 196(4):1112-6. PubMed ID: 27150425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
    Velho PI; Eisenberger MA
    J Clin Oncol; 2018 Oct; 36(30):3059-3060. PubMed ID: 30188787
    [No Abstract]   [Full Text] [Related]  

  • 15. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
    Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
    Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
    Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
    J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
    Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
    Verzoni E; De Giorgi U; Derosa L; Caffo O; Boccardo F; Facchini G; Porcu L; De Vincenzo F; Zaniboni A; Chiuri VE; Fratino L; Santini D; Adamo V; De Vivo R; Dinota A; Messina C; Ricotta R; Caserta C; Scavelli C; Susi M; Tartarone A; Surace G; Mosca A; Bruno M; Barni S; Grassi P; Procopio G
    Oncotarget; 2016 Jun; 7(26):40085-40094. PubMed ID: 27223078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early use of abiraterone and radium-223 in metastatic prostate cancer.
    Hindié E; Morgat C
    Lancet Oncol; 2019 May; 20(5):e229. PubMed ID: 31044706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.